Experimental oral drug blocks SARS-CoV-2 replication in mice

Experimental oral drug blocks SARS-CoV-2 replication in mice
Image: Intellect (generated)

In short: Researchers discovered S-217622, a new oral drug candidate designed to block the SARS-CoV-2 enzyme 3CL protease, using virtual and biological screening followed by structure-based optimization. In laboratory tests, the compound showed antiviral activity against several SARS-CoV-2 variants, and in mice it reduced the amount of virus replicating in the lungs in a dose-dependent way.

Oral antiviral pills that are easy to take at home could complement vaccines in treating COVID-19, and this compound is notable as an early noncovalent, non-peptide inhibitor of a key viral enzyme. The findings so far come from cell-based (in vitro) experiments and animal studies in mice, not from human trials, so whether S-217622 is safe or effective in people is not yet known.

Why it matters: An experimental oral drug blocked SARS-CoV-2 replication in mice, an early step that still needs testing in humans.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/technology-research-researchers-identify-a-new-oral-candidate-for-inhibiting-sar.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…